Abstract
Lung cancer is the leading cause of malignancy-related mortality worldwide. Metastases, which account for 90% of lung cancer deaths, frequently target the skeleton, leading to rapid deterioration in quality of life and premature death. The molecular mechanism underlying this progression, especially the development of bone metastases, is largely unknown. MicroRNAs (miRNAs) are small, endogenous, noncoding RNAs that function as negatively posttranscriptional gene regulators. Changes in miRNAs, which may exhibit either oncogenic or tumor suppressive activity, are common in lung cancer. Over-expressed miRNAs may contribute to oncogenesis by down-regulating tumor suppressors, whereas the loss of selected miRNAs may negatively regulate oncogenes or factors related to tumorigenesis and progression. MiRNAs may activate or repress metastases. Specific miRNA expression profiles may correlate with the response in treatment. We summarize recent findings and patents in the pathological roles of miRNAs in the progression and bone metastases in lung cancer, and discuss the diagnostic and therapeutic options in the clinical management of lung cancer.
Keywords: Biomarker, bone metastases, lung cancer, miRNA, oncogenesis, squamous cell carcinoma.
Recent Patents on Anti-Cancer Drug Discovery
Title:MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Volume: 10 Issue: 2
Author(s): Qian Zhao, Ping Li, Junrong Ma and Xijie Yu
Affiliation:
Keywords: Biomarker, bone metastases, lung cancer, miRNA, oncogenesis, squamous cell carcinoma.
Abstract: Lung cancer is the leading cause of malignancy-related mortality worldwide. Metastases, which account for 90% of lung cancer deaths, frequently target the skeleton, leading to rapid deterioration in quality of life and premature death. The molecular mechanism underlying this progression, especially the development of bone metastases, is largely unknown. MicroRNAs (miRNAs) are small, endogenous, noncoding RNAs that function as negatively posttranscriptional gene regulators. Changes in miRNAs, which may exhibit either oncogenic or tumor suppressive activity, are common in lung cancer. Over-expressed miRNAs may contribute to oncogenesis by down-regulating tumor suppressors, whereas the loss of selected miRNAs may negatively regulate oncogenes or factors related to tumorigenesis and progression. MiRNAs may activate or repress metastases. Specific miRNA expression profiles may correlate with the response in treatment. We summarize recent findings and patents in the pathological roles of miRNAs in the progression and bone metastases in lung cancer, and discuss the diagnostic and therapeutic options in the clinical management of lung cancer.
Export Options
About this article
Cite this article as:
Zhao Qian, Li Ping, Ma Junrong and Yu Xijie, MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment, Recent Patents on Anti-Cancer Drug Discovery 2015; 10 (2) . https://dx.doi.org/10.2174/1574892810666150120163617
DOI https://dx.doi.org/10.2174/1574892810666150120163617 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2)
Current Cancer Drug Targets Subject index to volume 1
Current HIV Research Recent Trends in Nanotechnology-Based Drugs and Formulations for Targeted Therapeutic Delivery
Recent Patents on Inflammation & Allergy Drug Discovery Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Molecular Targets for the Treatment of Multiple Myeloma
Current Cancer Drug Targets Biodegradable Polymeric Nanoparticles as the Delivery Carrier for Drug
Current Drug Delivery Harnessing Phage Display for the Discovery of Peptide-Based Drugs and Monoclonal Antibodies
Current Medicinal Chemistry Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution
Current Molecular Medicine Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension
Current Vascular Pharmacology Epidermal Growth Factor Receptor and its Trafficking Regulation by Acetylation: Implication in Resistance and Exploring the Newer Therapeutic Avenues in Cancer
Current Topics in Medicinal Chemistry A Comparison of the Inhibitory Effects of Anti-Cancer Drugs on Thioredoxin Reductase and Glutathione S-Transferase in Rat Liver
Anti-Cancer Agents in Medicinal Chemistry Anticancer Antioxidant Regulatory Functions of Phytochemicals
Current Medicinal Chemistry The Re-Emergence of Aerosol Gene Delivery: A Viable Approach to Lung Cancer Therapy
Current Cancer Drug Targets The Nature of Immunological Reaction in the Peripheral Airways of Cigarette Smokers
Current Respiratory Medicine Reviews Regulatory Circuitries Coordinated by Transcription Factors and microRNAs at the Cornerstone of Hematopoietic Stem Cell Self-Renewal and Differentiation
Current Stem Cell Research & Therapy Novel Mechanisms of Anticancer Activities of Green Tea Component Epigallocatechin- 3-Gallate
Anti-Cancer Agents in Medicinal Chemistry The Role of Mass Spectrometry in the “Omics” Era
Current Organic Chemistry Mesenchymal Stem Cell Therapy in Intracerebral Haemorrhagic Stroke
Current Medicinal Chemistry Methodological Aspects and Applications of In Vivo Imaging of Apoptosis in Oncology: An Illustrative Review
Current Medical Imaging